CORE--CLINICAL RESEARCH AND PATIENT CARE

核心——临床研究和患者护理

• 批准号: 6325897
• 负责人: William C. Mentzer
• 金额: $ 23.29万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-04-01 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6325897
• 关键词: biomedical facility; blood disorder chemotherapy; bone marrow transplantation; cerebral ischemia /hypoxia; hematopoietic tissue transplantation; human subject; human therapy evaluation; hydroxyurea; longitudinal human study; magnetic resonance imaging; medical complication; patient care; positron emission tomography; sickle cell anemia; sickling inhibitor

The clinical research and patient care core programs for the Northern California Comprehensive Sickle Cell Center (NCCSCC) application are based in the East Bay at Children's Hospital and Highland Hospital Oakland, and in the West Bay at San Francisco, General Hospital/University of California, San Francisco. The large patient population enrolled in these cooperative clinical programs provides an ideal source to conduct clinical and basic research projects as proposed. Since 1978, the multi- disciplinary staff of our center has met on a regular basis to discuss patient management issues, evaluate ongoing clinical and basic research projects, and plan new research. The success of these interactions is reflected in our publications related to basic and clinical research on sickle cell disease (listed in the summary progress report), in our participation in national efforts to establish treatment guidelines for patients with sickle cell disease and in our contribution to understanding the etiology and mechanism of sickle cell clinical complications. This application describes a number of new clinical research projects: 1) anti- sickling agents including hydroxyurea-sodium phenylbutyrate, magnesium therapy, clotrimazole; 2) Deferiprone (L1) therapy; 3) CNS ischemia; 4) bone marrow transplant in the treatment of sickle cell disease; 5) core blood transplant and the development of a minority cord blood donor program. In addition the above project, the core will proved necessary samples for many basic research projects. In summary, the strength of the clinical core in our center application will enable us to complete successfully the proposed clinical research projects, participate in basic research and improve the understanding of the etiology and treatment of many sickle cell complications.

北方的临床研究和病人护理核心项目 加州综合镰状细胞中心（NCCSCC）的申请是基于 在东湾的儿童医院和奥克兰高地医院， 在旧金山弗朗西斯科的西湾，总医院/大学 加州，旧金山弗朗西斯科。入组这些研究的大量患者人群 合作临床项目提供了一个理想的来源，进行临床 和基础研究项目。自1978年以来，多... 我们中心的纪律人员定期开会讨论 患者管理问题，评估正在进行的临床和基础研究 项目，并计划新的研究。这些互动的成功是 反映在我们与基础和临床研究有关的出版物中， 镰状细胞病（列于简要进展报告），在我们的 参与国家制定治疗准则的努力， 镰状细胞病患者以及我们对理解 镰状细胞临床并发症的病因和机制。这 申请介绍了一些新的临床研究项目：1）抗- 镰状化剂，包括羟基脲-苯丁酸钠、镁 治疗，克霉唑; 2）去铁酮（L1）治疗; 3）CNS缺血; 4） 骨髓移植治疗镰状细胞病; 5）核心 血液移植和少数民族脐带血供体的发展 程序.除了上述项目外，核心将被证明是必要的 许多基础研究项目的样本。总而言之， 我们中心应用程序中的临床核心将使我们能够完成 成功提出临床科研项目，参与基础 研究和提高对病因和治疗的理解 许多镰状细胞并发症。